Cargando…
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
BACKGROUND: Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 single-domain antibodies (sdAbs) that can be used to trace CD38(+) tumour ce...
Autores principales: | Duray, Elodie, Lejeune, Margaux, Baron, Frederic, Beguin, Yves, Devoogdt, Nick, Krasniqi, Ahmet, Lauwers, Yoline, Zhao, Yong Juan, D’Huyvetter, Matthias, Dumoulin, Mireille, Caers, Jo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561907/ https://www.ncbi.nlm.nih.gov/pubmed/34727950 http://dx.doi.org/10.1186/s13045-021-01171-6 |
Ejemplares similares
-
Radiotheranostic Agents in Hematological Malignancies
por: Caers, Jo, et al.
Publicado: (2022) -
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2021) -
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014) -
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020) -
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
por: Dekempeneer, Yana, et al.
Publicado: (2016)